OCEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International, a clinical-stage biotechnology company, commented today on a recent research report from John Hopkins Children’s Center in the peer-reviewed publication Nature journal Communications Biology1.
Data generated by the researchers independent of Therapeutic Solutions International, unequivocally demonstrated that sulforaphane, one of the ingredients in the Company’s QuadraMune™ product, suppresses multiplication and activity of SARS-CoV-2, the virus responsible for Covid-19.
In the publication abstract, the researchers concluded, “Our results suggest that sulforaphane should be explored as a potential agent for the prevention or treatment of coronavirus infections.”
“As a physician who is currently leading an FDA-cleared Phase III clinical trial for advanced COVID-19 patients, I am extremely excited to see that our nutraceutical program is receiving independent validation based on research published from world-class institutions,” said Dr. James Veltmeyer, Chief Medical Officer of the Company.
The Company possesses two issued United States Patents for use of QuadraMune™ in the area of Immune Modulation (#11,229,674) and treatment of Coronavirus (#11,266,707). After the Company filed its first patent on QuadraMune on May 5th, 2020, numerous independent publications appeared supporting the use of the four ingredients in QuadraMune for treatment of COVID-192.
“Our successes are based on the fact that we at Therapeutic Solutions International are focused number one on science and leveraging science to help people,” said Timothy Dixon, President, and CEO of the Company. “Science is a force that cannot be stopped, we are fortunate to have internationally renowned scientists as part of our team, who develop out of the box ideas such as QuadraMune, which are now in the process of being validated internally and externally.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com.
1 Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice | Communications Biology (nature.com)
2 Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing (yahoo.com)